Cytek Biosciences Third Quarter 2026 Earnings Conference Call - CYTEK BIOSCIENCES INC

Financial Performance:

• Q3 2026 revenue reached $53.2 million, representing a 2% year-over-year increase.
• GAAP gross margin improved significantly to 59% (Q2 2025: 53%; Q3 2025: 53%), a gain of nearly 600 basis points.
• Total operating expenses were $39.6 million (up 8% YoY), driven largely by a $3 million increase in legal expenses related to patent litigation.
• Net loss was $6.1 million (compared to $5.5 million loss YoY), while Adjusted EBITDA was $0.7 million (down from $2.5 million in Q2 2025, largely due to lower investment income).
• Service revenue grew 13% YoY to $19.1 million, accounting for 36% of the trailing twelve-month revenue.
• High-end full-spectrum profiling instrument revenue grew 11%, while the installed base increased by 140 units to 4,073.
• Cash, cash equivalents, and marketable securities totaled $256 million as of September 30, 2026.

Guidance and Future Outlook:

• Full-year 2026 revenue guidance is maintained at a midpoint of $209.5 million, with the range narrowed to $208–$211 million.
• Full-year 2026 Adjusted EBITDA is expected to be approximately break-even, supported by a strong Q4 seasonality and reduced legal expenses.
• Q4 revenue is forecasted to be meaningfully higher than Q3, consistent with typical year-end customer purchasing patterns.
• Management expects to outgrow the market in 2027, driven by new product launches and continued market share gains.
• Borealis analyzer with full imaging capability is scheduled for commercial launch in fiscal year 2027.
• A new organizational structure intended to support long-term growth will be implemented starting in 2027, having been postponed from mid-2026.

Business Segments and Product Lines:

• Geography: U.S. revenue grew 12% YoY; EMEA returned to modest growth (1% YoY); APAC grew 5% sequentially but was down 25% YoY due to a strong prior year comparison and macroeconomic factors.
• Instruments: Aurora and Aurora Evo placements grew 23% YoY (EVO placements nearly doubled); Borealis early access program doubled in size during Q3.
• Service & Reagents: Recurring revenue base (service + reagents) grew to 36% of total revenue; Service gross margin expanded to 53%.
• New Launches: Launched "SiteCloud," an end-to-end cloud analysis platform integrating panel design and data analysis; introduced a new premium subscription tier (SiteCloud Premium).
• Customer Mix: Academic and government revenue surged 38% YoY to $24.5 million; Biopharma/CRO/Distributor revenue declined 17% YoY.

Market and Competitive Landscape:

• Competition in the U.S. remains strong, with high demand for high-throughput, automated full-spectrum profiling instruments.
• The market environment is viewed as generally positive, with headwinds from early 2025 abating and academic/government spending strengthening.
• Management anticipates maintaining leadership in the high-end segment while investing in low-to-mid-range instruments and reagent portfolios.
• APAC weakness was attributed to macroeconomic factors and a heavy reliance on distributor sales in that region.

Risks and Challenges:

• Patent Litigation: A Delaware jury found infringement on three claims (but not on legal criteria) and found infringement on a fourth under the "doctrine of equivalence"; the company plans to appeal and has filed post-trial motions.
• Legal Costs: One-time litigation expenses are expected to drop by $3–$4 million in Q4 as the trial phase concludes.
• Macroeconomics: APAC and China markets face headwinds affecting distributor sales.
• Operational Risks: Potential risks associated with the mid-year rollout of the new business unit structure were deemed too high for 2026.

Management Commentary and Tone:

• Tone was confident and optimistic regarding the strength of the technology portfolio and the company's ability to outgrow the market.
• Management highlighted "solid" Q3 results driven by high-end product success and operational efficiency (Singapore manufacturing transfer).
• Wenbin Zhong (CEO) expressed confidence in the future, citing the Borealis launch and organizational improvements, while Bill McComb (CFO) emphasized the financial discipline in achieving break-even EBITDA.

Analyst Questions and Answers:

• 2027 Growth: Management declined to provide specific 2027 guidance but reiterated expectations to outgrow the market and peers.
• Service Revenue: Service growth is expected to continue at a double-digit rate in Q4, with product revenue filling the balance of the Q4 mix.
• Market Trends: The market is perceived as having improved compared to early 2025, with a generally positive environment.
• SiteCloud Strategy: SiteCloud is positioned as a strategic moat to retain customers within the ecosystem rather than a primary standalone profit driver.
• Biopharma Segment: Biopharma revenue is up 3% YTD; Q3 weakness was largely due to distributor sales in APAC, while U.S. biopharma demand remains robust for year-end budget spending.
• Supply Chain: Supply constraints are not a major issue; the company is currently shipping most booked orders within the quarter, though production rates for high-demand models (Aurora Evo, Borealis) are increasing.

Other Key Points:

• Manufacturing transfer from Seattle to Singapore is complete, resulting in lower costs, reduced tariffs, and improved supply flexibility.
• The total SiteCloud user base approached 30,000, representing a >20% increase since the start of the year.
• The company is leveraging its patent victory (3 out of 4 claims) to assert legal standing, though the case remains active.
• No changes to product offerings or shipping capabilities were required due to the litigation outcome.